PBS Biotech secures $10 million to expand cell therapy manufacturing equipment portfolio

The capital will be used to expand and industrialise the company's range of single-use bioreactor systems and contract process development services

Specifically, the financing will enable the company to expand and industrialise its portfolio of single-use bioreactor systems and contract process development services.

PBS Biotech uses proprietary Vertical-Wheel technology to achieve unique mixing properties and environmental conditions for cell therapy products. According to the company, these have proven superior to traditional 'stirred-tank' bioreactors in multiple published studies.

In addition, the company's in-house bioprocess R&D facility provides process expertise and development services to assist cell therapy customers in scaling up from research phases to clinical and commercial phases.

Although scalable conditions enabled by these bioreactor systems are ideal for a wide range of therapeutic products, they are particularly well-suited for induced pluripotent stem cell (iPSC), mesenchymal stem cell (MSC), and exosome-based therapy manufacturing.

Companies in this space are seeking cures for diabetes and heart disease utilising these novel regenerative medicines.

Brian Lee, CEO of PBS Biotech, said that with the funding, the company will provide a "full line of GMP-qualified bioreactor systems to support the clinical studies and commercialization needs of our customers".